vs
Ally Financial Inc.（ALLY）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Ally Financial Inc.の直近四半期売上が大きい（$301.0M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.1倍）。Ally Financial Inc.の純利益率が高く（108.6% vs 16.5%、差は92.2%）。Prestige Consumer Healthcare Inc.の前年同期比売上増加率が高い（-2.4% vs -3.2%）。過去8四半期でAlly Financial Inc.の売上複合成長率が高い（11.1% vs 1.2%）
Ally Financial Inc.はアメリカ合衆国デラウェア州に設立登記され、ミシガン州デトロイトに本社を置く銀行持株会社です。自動車金融、ダイレクトバンクによるオンラインバンキング、企業向け融資、車両保険、住宅ローンのほか、分割販売やリース契約といった関連金融サービスを提供しています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
ALLY vs PBH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $301.0M | $283.4M |
| 純利益 | $327.0M | $46.7M |
| 粗利率 | — | 55.5% |
| 営業利益率 | — | 29.1% |
| 純利益率 | 108.6% | 16.5% |
| 売上前年比 | -3.2% | -2.4% |
| 純利益前年比 | 333.6% | -23.5% |
| EPS（希薄化後） | $0.97 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $301.0M | $283.4M | ||
| Q3 25 | $308.0M | $274.1M | ||
| Q2 25 | $312.0M | $249.5M | ||
| Q1 25 | $323.0M | $296.5M | ||
| Q4 24 | $311.0M | $290.3M | ||
| Q3 24 | $319.0M | $283.8M | ||
| Q2 24 | $324.0M | $267.1M | ||
| Q1 24 | $244.0M | $277.0M |
| Q4 25 | $327.0M | $46.7M | ||
| Q3 25 | $398.0M | $42.2M | ||
| Q2 25 | $352.0M | $47.5M | ||
| Q1 25 | $-225.0M | $50.1M | ||
| Q4 24 | $-140.0M | $61.0M | ||
| Q3 24 | $357.0M | $54.4M | ||
| Q2 24 | $294.0M | $49.1M | ||
| Q1 24 | $157.0M | $49.5M |
| Q4 25 | — | 55.5% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 57.3% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 55.5% | ||
| Q2 24 | — | 54.7% | ||
| Q1 24 | — | 54.8% |
| Q4 25 | — | 29.1% | ||
| Q3 25 | — | 29.1% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | -87.9% | 29.8% | ||
| Q4 24 | 56.3% | 31.7% | ||
| Q3 24 | 73.0% | 29.7% | ||
| Q2 24 | 79.3% | 27.0% | ||
| Q1 24 | 70.1% | 29.7% |
| Q4 25 | 108.6% | 16.5% | ||
| Q3 25 | 129.2% | 15.4% | ||
| Q2 25 | 112.8% | 19.0% | ||
| Q1 25 | -69.7% | 16.9% | ||
| Q4 24 | -45.0% | 21.0% | ||
| Q3 24 | 111.9% | 19.2% | ||
| Q2 24 | 90.7% | 18.4% | ||
| Q1 24 | 64.3% | 17.9% |
| Q4 25 | $0.97 | $0.97 | ||
| Q3 25 | $1.18 | $0.86 | ||
| Q2 25 | $1.04 | $0.95 | ||
| Q1 25 | $-0.82 | $1.00 | ||
| Q4 24 | $-0.54 | $1.22 | ||
| Q3 24 | $1.06 | $1.09 | ||
| Q2 24 | $0.86 | $0.98 | ||
| Q1 24 | $0.42 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $10.0B | $62.4M |
| 総負債低いほど良い | $17.1B | $1.0B |
| 株主資本純資産 | $15.5B | $1.8B |
| 総資産 | $196.0B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 1.10× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $10.0B | $62.4M | ||
| Q3 25 | $10.2B | $119.1M | ||
| Q2 25 | $10.6B | $139.5M | ||
| Q1 25 | $10.4B | $97.9M | ||
| Q4 24 | $10.3B | $50.9M | ||
| Q3 24 | $8.6B | $51.5M | ||
| Q2 24 | $7.4B | $34.3M | ||
| Q1 24 | $8.2B | $46.5M |
| Q4 25 | $17.1B | $1.0B | ||
| Q3 25 | $16.7B | $993.1M | ||
| Q2 25 | $15.9B | $992.7M | ||
| Q1 25 | $16.5B | $992.4M | ||
| Q4 24 | $17.5B | $992.0M | ||
| Q3 24 | $16.8B | $1.1B | ||
| Q2 24 | $16.0B | $1.1B | ||
| Q1 24 | $17.0B | $1.1B |
| Q4 25 | $15.5B | $1.8B | ||
| Q3 25 | $15.1B | $1.8B | ||
| Q2 25 | $14.5B | $1.9B | ||
| Q1 25 | $14.2B | $1.8B | ||
| Q4 24 | $13.9B | $1.8B | ||
| Q3 24 | $14.7B | $1.7B | ||
| Q2 24 | $13.9B | $1.7B | ||
| Q1 24 | $13.7B | $1.7B |
| Q4 25 | $196.0B | $3.5B | ||
| Q3 25 | $191.7B | $3.4B | ||
| Q2 25 | $189.5B | $3.4B | ||
| Q1 25 | $193.3B | $3.4B | ||
| Q4 24 | $191.8B | $3.3B | ||
| Q3 24 | $193.0B | $3.3B | ||
| Q2 24 | $192.5B | $3.3B | ||
| Q1 24 | $192.9B | $3.3B |
| Q4 25 | 1.10× | 0.56× | ||
| Q3 25 | 1.11× | 0.54× | ||
| Q2 25 | 1.09× | 0.54× | ||
| Q1 25 | 1.16× | 0.54× | ||
| Q4 24 | 1.26× | 0.55× | ||
| Q3 24 | 1.14× | 0.61× | ||
| Q2 24 | 1.15× | 0.65× | ||
| Q1 24 | 1.25× | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $640.0M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $75.3M |
| FCFマージンFCF / 売上 | — | 26.6% |
| 設備投資強度設備投資 / 売上 | — | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 1.96× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | — | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $640.0M | $78.3M | ||
| Q3 25 | $1.2B | $57.5M | ||
| Q2 25 | $947.0M | $79.0M | ||
| Q1 25 | $940.0M | $61.8M | ||
| Q4 24 | $620.0M | $65.1M | ||
| Q3 24 | $992.0M | $69.8M | ||
| Q2 24 | $1.6B | $54.8M | ||
| Q1 24 | $1.3B | $66.9M |
| Q4 25 | — | $75.3M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | — | $78.2M | ||
| Q1 25 | — | $58.4M | ||
| Q4 24 | — | $63.5M | ||
| Q3 24 | — | $67.8M | ||
| Q2 24 | — | $53.6M | ||
| Q1 24 | — | $63.8M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 31.3% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 21.9% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 23.0% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | 1.96× | 1.68× | ||
| Q3 25 | 3.02× | 1.36× | ||
| Q2 25 | 2.69× | 1.66× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | 2.78× | 1.28× | ||
| Q2 24 | 5.36× | 1.12× | ||
| Q1 24 | 8.54× | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ALLY
| Noninsurance Contracts | $242.0M | 80% |
| Brokerage Commissionsand Other | $21.0M | 7% |
| Commercial Portfolio Segment | $19.0M | 6% |
| Other | $13.0M | 4% |
| Banking Fees And Interchange Income | $5.0M | 2% |
| Brokered Agent Commissions | $1.0M | 0% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
